RAM
REGN icon

RK Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

RK Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.77M Buy
12,660
+14
+0.1% +$9.51K 9.22% 2
2025
Q3 		$7.11M Buy
12,646
+44
+0.3% +$24.9K 6.46% 3
2025
Q2 		$6.62M Buy
12,602
+39
+0.3% +$21.8K 6.38% 4
2025
Q1 		$7.97M Buy
12,563
+2,574
+26% +$1.77M 7.36% 2
2024
Q4 		$7.12M Buy
9,989
+896
+10% +$752K 5.82% 4
2024
Q3 		$9.56M Sell
9,093
-14
-0.2% -$15.6K 7.35% 2
2024
Q2 		$9.57M Sell
9,107
-112
-1% -$109K 8.27% 3
2024
Q1 		$8.87M Sell
9,219
-180
-2% -$171K 7.22% 4
2023
Q4 		$8.26M Buy
9,399
+502
+6% +$413K 6.85% 4
2023
Q3 		$7.32M Sell
8,897
-15
-0.2% -$11.8K 6.85% 4
2023
Q2 		$6.4M Hold
8,912
– – 5.93% 5
2023
Q1 		$7.32M Sell
8,912
-106
-1% -$79.9K 7.25% 5
2022
Q4 		$6.51M Buy
+9,018
New +$6.65M 6.24% 6
2022
Q1 		$284K Buy
+407
New +$257K 0.28% 18

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RK Asset Management's REGN Position: Q4 2025 in Review

RK Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.11% in Q4 2025, buying an estimated $9.51K and bringing the position to 12,660 shares worth $9.77M. The position accounts for 9.22% of the portfolio, ranked #2.

RK Asset Management first reported a position in REGN in Q1 2022 and has held it in 14 quarters since. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • RK Asset Management held 12,660 shares of Regeneron Pharmaceuticals worth $9.77M as of Q4 2025.
  • RK Asset Management bought 14 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $9.51K.
  • Regeneron Pharmaceuticals made up 9.22% of RK Asset Management's portfolio in Q4 2025, its #2 holding.
  • RK Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on RK Asset Management's 13F filing for Q4 2025, filed 5 Jan 2026.